Compare FA & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FA | IDYA |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.5B |
| IPO Year | 2021 | 2019 |
| Metric | FA | IDYA |
|---|---|---|
| Price | $20.27 | $35.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 16 |
| Target Price | $15.67 | ★ $52.86 |
| AVG Volume (30 Days) | ★ 1.8M | 851.2K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.97 | 61.90 |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $1,574,389,000.00 | $218,710,000.00 |
| Revenue This Year | $8.42 | N/A |
| Revenue Next Year | $7.26 | $201.05 |
| P/E Ratio | $2,039.00 | ★ N/A |
| Revenue Growth | 83.02 | ★ 3024.43 |
| 52 Week Low | $8.82 | $22.09 |
| 52 Week High | $22.78 | $40.58 |
| Indicator | FA | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 52.00 | 52.91 |
| Support Level | $19.05 | $33.23 |
| Resistance Level | $20.97 | $38.11 |
| Average True Range (ATR) | 0.95 | 1.40 |
| MACD | -0.25 | -0.25 |
| Stochastic Oscillator | 26.91 | 54.24 |
First Advantage Corp is a provider of software and data in the Human Resources technology industry. The company provides end-to-end identity solutions, criminal background screening, credential verifications, drug and health screening, and continuous risk monitoring. It combines AI-powered proprietary technology platforms with proprietary data, primary source data, and third-party data. Its reportable segments are First Advantage Americas, First Advantage International, and Sterling. The company generates maximum revenue from the Sterling segment, which provides similar services as compared to First Advantage's Americas and International segments on a global basis. Geographically, the company generates the majority of its revenue from the United States.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.